![NMD Pharma Raises $39.7 Million to Advance Pipeline Targeting Rare Neuromuscular Disorders - Global Genes NMD Pharma Raises $39.7 Million to Advance Pipeline Targeting Rare Neuromuscular Disorders - Global Genes](https://globalgenes.org/wp-content/uploads/2022/02/Thomas-Holm-Pedersen-NMD-263x263.jpg)
NMD Pharma Raises $39.7 Million to Advance Pipeline Targeting Rare Neuromuscular Disorders - Global Genes
![Novo Seeds portfolio company NMD Pharma reports positive top-line Phase I/IIa data in myasthenia gravis - Startup Weekly Novo Seeds portfolio company NMD Pharma reports positive top-line Phase I/IIa data in myasthenia gravis - Startup Weekly](https://startup-weekly.com/connectors/images/Novo%20Seeds-StartupWeekly%20.png)
Novo Seeds portfolio company NMD Pharma reports positive top-line Phase I/IIa data in myasthenia gravis - Startup Weekly
![Following a compound from start to finish - Nordic Life Science – the leading Nordic life science news service Following a compound from start to finish - Nordic Life Science – the leading Nordic life science news service](https://nordiclifescience.org/wp-content/public_html/2022/07/anders-findsen-nmd-pharma.jpg)
Following a compound from start to finish - Nordic Life Science – the leading Nordic life science news service
![NMD Pharma is about to start a combined Phase I/IIa clinical trial with its ClC-1 channel inhibitor in healthy subjects and patients with myasthenia gravis – ION CHANNEL LIBRARY NMD Pharma is about to start a combined Phase I/IIa clinical trial with its ClC-1 channel inhibitor in healthy subjects and patients with myasthenia gravis – ION CHANNEL LIBRARY](https://www.ionchannellibrary.com/wp-content/uploads/2020/07/stethoscope.jpg)